

FOSUN PHARMA

INTERNATIONAL FOR A GOOD HEALTH

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

Stock

Our Vision

Become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

Our Mission

Better health for families worldwide.

Contents

2	C	a	m
4	a	a	■
5	▼	a	a m D a A a
35	§	a	D
41	m	C	C a § a m
42	m	C	C a § a m C m m
43	m	C	C a § a m a a
45	m	C	C a § a m C a
47	m	C	C a § a m Ca w
49	▲	m	C C a a a § a m
78	D		

Directors

Executive Directors

- ▼ . C (陳啟宇) (Chairman)
- ▼ . 姚 方 (姚方) (Co-Chairman)
- ▼ . 吳 以 芳 (吳以芳) (President and Chief Executive Officer)

Non-executive Directors

- ▼ . 徐 曉 亮 (徐曉亮)
- ▼ . (龔平)¹
- ▼ . 潘 東 輝 D (潘東輝)¹
- ▼ . 梁 劍 峰 (梁劍峰)²
- ▼ . 王 燦 C (王燦)³
- ▼ . 沐 海 寧 (沐海寧)⁵

Independent Non-executive Directors

- ▼ . 江 憲 (江憲)

Stock Abbreviation

本公司股票缩写为 A

Share Listing

本公司股票在 A 股市场上市

股票代码 : 600196

本公司股票在 H 股市场上市

股票代码 : 02196

A Share Registrar and Transfer Office in the PRC

本公司 A 股在 DCC 及 C 股市场上市 (DCC)

本公司 A 股在 B 股市场上市

本公司 A 股在 B 股市场上市

166 股 A 股在 B 股市场上市

D

本公司 A 股在 C 股市场上市

H Share Registrar and Transfer Office in Hong Kong

本公司 H 股在 H 股市场上市

54, 183 股 H 股在 H 股市场上市

183 股 H 股在 H 股市场上市

Company's Website

://www. 本公司网站

¹ A 30 2020

² 17 2020

³ 21 2020

⁴ A 21 2020

⁵ 30 2020

⁶ A 30 2020

Financial

		Six months ended 30 June	
		2020	2019
		RMB million	B m
Operating results			
		13,965	14,085
		7,749	8,486
		1,292	1,490
		2,302	2,196
		1,715	1,516
B DA		3,566	3,483
Profitability			
		55.49%	60.25%
		9.25%	10.58%
		13.67%	12.92%

FINANCIAL REVIEW

D 2019. 0.85% ▼B13,965 2019.

D 2019. 4.83% 13.10%, 2019. (1) 2019- C, (2) (B), (C) (2,000), B224 B100 (3) 2.6 (4) B 29.15%.

D 2019. 13.56% ▼B0.67

REVENUE

D 2019. 0.85% ▼B13,965 B9,894 B4,071 29.15%.

D 2019. 7.97% B9,952

D A

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

A 30 2020, 823,358 m 821,137 m 31 D 2019 m

Management

D A

Maturity Structure of Outstanding Debts

	30 June 2020	31 D 2019
1	12,405	8,560
2	7,834	6,860
5	2,633	5,396
5	483	321
	23,358	21,137

Available Facilities

A 30 2020, B9,750 m, B32,709 m
B48,320 m B15,611 m

Collateral and Pledged Assets

A 30 2020, B217
B134 m B396 m B303 m
B5 m B4 m

D 16

Cash Flow

2019.

	January – June 2020	2019
	1,461	1,450
	(2,379)	(1,079)
	827	(496)
	(91)	(125)
	8,284	7,175
	8,177	7,052

D
B1,812 m

A 30 2020, B3,450 m . 18

A 30 2020, 3 3 3 .

D
2019: 6.37 ମି.).

D A

D

$m^A \quad m^B \quad w^A \quad w^B$

: m^C : ∇B

D	,						&D	.			&D		▼B1,689	
m	,			25.02%		m				2019.			&D	
▼B1,204	m	,				▼B355	m		41.81%		m			2019.

D
 7.97%
 B1,116
 B1,115
 7.40%
 9.54%
 27.92%
 15.4%
 46.27%
 2019
 B9,952
 B1,541
 B335
 B1,059
 10.6%

5. ¹ C D-19 ² ³ ⁴ ⁵ ⁶ ⁷ ⁸ ⁹ ¹⁰ ¹¹ ¹² ¹³ ¹⁴ ¹⁵ ¹⁶ ¹⁷ ¹⁸ ¹⁹ ²⁰ ²¹ ²² ²³ ²⁴ ²⁵ ²⁶ ²⁷ ²⁸ ²⁹ ³⁰ ³¹ ³² ³³ ³⁴ ³⁵ ³⁶ ³⁷ ³⁸ ³⁹ ⁴⁰ ⁴¹ ⁴² ⁴³ ⁴⁴ ⁴⁵ ⁴⁶ ⁴⁷ ⁴⁸ ⁴⁹ ⁵⁰ ⁵¹ ⁵² ⁵³ ⁵⁴ ⁵⁵ ⁵⁶ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶¹ ⁶² ⁶³ ⁶⁴ ⁶⁵ ⁶⁶ ⁶⁷ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁷² ⁷³ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁷ ⁷⁸ ⁷⁹ ⁸⁰ ⁸¹ ⁸² ⁸³ ⁸⁴ ⁸⁵ ⁸⁶ ⁸⁷ ⁸⁸ ⁸⁹ ⁹⁰ ⁹¹ ⁹² ⁹³ ⁹⁴ ⁹⁵ ⁹⁶ ⁹⁷ ⁹⁸ ⁹⁹ ¹⁰⁰ ¹⁰¹ ¹⁰² ¹⁰³ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹⁰⁹ ¹¹⁰ ¹¹¹ ¹¹² ¹¹³ ¹¹⁴ ¹¹⁵ ¹¹⁶ ¹¹⁷ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹²¹ ¹²² ¹²³ ¹²⁴ ¹²⁵ ¹²⁶ ¹²⁷ ¹²⁸ ¹²⁹ ¹³⁰ ¹³¹ ¹³² ¹³³ ¹³⁴ ¹³⁵ ¹³⁶ ¹³⁷ ¹³⁸ ¹³⁹ ¹⁴⁰ ¹⁴¹ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁶ ¹⁴⁷ ¹⁴⁸ ¹⁴⁹ ¹⁵⁰ ¹⁵¹ ¹⁵² ¹⁵³ ¹⁵⁴ ¹⁵⁵ ¹⁵⁶ ¹⁵⁷ ¹⁵⁸ ¹⁵⁹ ¹⁶⁰ ¹⁶¹ ¹⁶² ¹⁶³ ¹⁶⁴ ¹⁶⁵ ¹⁶⁶ ¹⁶⁷ ¹⁶⁸ ¹⁶⁹ ¹⁷⁰ ¹⁷¹ ¹⁷² ¹⁷³ ¹⁷⁴ ¹⁷⁵ ¹⁷⁶ ¹⁷⁷ ¹⁷⁸ ¹⁷⁹ ¹⁸⁰ ¹⁸¹ ¹⁸² ¹⁸³ ¹⁸⁴ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵ ¹⁹⁶ ¹⁹⁷ ¹⁹⁸ ¹⁹⁹ ²⁰⁰ ²⁰¹ ²⁰² ²⁰³ ²⁰⁴ ²⁰⁵ ²⁰⁶ ²⁰⁷ ²⁰⁸ ²⁰⁹ ²¹⁰ ²¹¹ ²¹² ²¹³ ²¹⁴ ²¹⁵ ²¹⁶ ²¹⁷ ²¹⁸ ²¹⁹ ²²⁰ ²²¹ ²²² ²²³ ²²⁴ ²²⁵ ²²⁶ ²²⁷ ²²⁸ ²²⁹ ²³⁰ ²³¹ ²³² ²³³ ²³⁴ ²³⁵ ²³⁶ ²³⁷ ²³⁸ ²³⁹ ²⁴⁰ ²⁴¹ ²⁴² ²⁴³ ²⁴⁴ ²⁴⁵ ²⁴⁶ ²⁴⁷ ²⁴⁸ ²⁴⁹ ²⁵⁰ ²⁵¹ ²⁵² ²⁵³ ²⁵⁴ ²⁵⁵ ²⁵⁶ ²⁵⁷ ²⁵⁸ ²⁵⁹ ²⁶⁰ ²⁶¹ ²⁶² ²⁶³ ²⁶⁴ ²⁶⁵ ²⁶⁶ ²⁶⁷ ²⁶⁸ ²⁶⁹ ²⁷⁰ ²⁷¹ ²⁷² ²⁷³ ²⁷⁴ ²⁷⁵ ²⁷⁶ ²⁷⁷ ²⁷⁸ ²⁷⁹ ²⁸⁰ ²⁸¹ ²⁸² ²⁸³ ²⁸⁴ ²⁸⁵ ²⁸⁶ ²⁸⁷ ²⁸⁸ ²⁸⁹ ²⁹⁰ ²⁹¹ ²⁹² ²⁹³ ²⁹⁴ ²⁹⁵ ²⁹⁶ ²⁹⁷ ²⁹⁸ ²⁹⁹ ³⁰⁰ ³⁰¹ ³⁰² ³⁰³ ³⁰⁴ ³⁰⁵ ³⁰⁶ ³⁰⁷ ³⁰⁸ ³⁰⁹ ³¹⁰ ³¹¹ ³¹² ³¹³ ³¹⁴ ³¹⁵ ³¹⁶ ³¹⁷ ³¹⁸ ³¹⁹ ³²⁰ ³²¹ ³²² ³²³ ³²⁴ ³²⁵ ³²⁶ ³²⁷ ³²⁸ ³²⁹ ³³⁰ ³³¹ ³³² ³³³ ³³⁴ ³³⁵ ³³⁶ ³³⁷ ³³⁸ ³³⁹ ³⁴⁰ ³⁴¹ ³⁴² ³⁴³ ³⁴⁴ ³⁴⁵ ³⁴⁶ ³⁴⁷ ³⁴⁸ ³⁴⁹ ³⁵⁰ ³⁵¹ ³⁵² ³⁵³ ³⁵⁴ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ ³⁵⁹ ³⁶⁰ ³⁶¹ ³⁶² ³⁶³ ³⁶⁴ ³⁶⁵ ³⁶⁶ ³⁶⁷ ³⁶⁸ ³⁶⁹ ³⁷⁰ ³⁷¹ ³⁷² ³⁷³ ³⁷⁴ ³⁷⁵ ³⁷⁶ ³⁷⁷ ³⁷⁸ ³⁷⁹ ³⁸⁰ ³⁸¹ ³⁸² ³⁸³ ³⁸⁴ ³⁸⁵ ³⁸⁶ ³⁸⁷ ³⁸⁸ ³⁸⁹ ³⁹⁰ ³⁹¹ ³⁹² ³⁹³ ³⁹⁴ ³⁹⁵ ³⁹⁶ ³⁹⁷ ³⁹⁸ ³⁹⁹ ⁴⁰⁰ ⁴⁰¹ ⁴⁰² ⁴⁰³ ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁰⁷ ⁴⁰⁸ ⁴⁰⁹ ⁴¹⁰ ⁴¹¹ ⁴¹² ⁴¹³ ⁴¹⁴ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²² ⁴²³ ⁴²⁴ ⁴²⁵ ⁴²⁶ ⁴²⁷ ⁴²⁸ ⁴²⁹ ⁴³⁰ ⁴³¹ ⁴³² ⁴³³ ⁴³⁴ ⁴³⁵ ⁴³⁶ ⁴³⁷ ⁴³⁸ ⁴³⁹ ⁴⁴⁰ ⁴⁴¹ ⁴⁴² ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁰ ⁴⁵¹ ⁴⁵² ⁴⁵³ ⁴⁵⁴ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶¹ ⁴⁶² ⁴⁶³ ⁴⁶⁴ ⁴⁶⁵ ⁴⁶⁶ <

9. A M.A M.A B.A B.A

W B :

: M C : ▼ B

Pharmaceutical manufacturing and R&D										Jan – Jun 2020	2019 (Note 1)	2019 (%)	
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 2)	1,767	1,807	2.19
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 3)	422	264	59.94
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 4)	1,800	2,331	22.77
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 5)	755	1,224	38.35
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 6)	1,248	1,140	9.49
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 7)	247	419	41.03
▼	2019	2020	2021	2022	2023	2024	2025	2026	2027	(Note 8)	452	675	32.97

Note 1:

(C) (A)

Note 2: $\nabla \cdot \mathbf{v} = \frac{\partial v_x}{\partial x} + \frac{\partial v_y}{\partial y} + \frac{\partial v_z}{\partial z}$, $\mathbf{v} \cdot \nabla = v_x \frac{\partial}{\partial x} + v_y \frac{\partial}{\partial y} + v_z \frac{\partial}{\partial z}$, $\nabla \times \mathbf{v} = \left(\frac{\partial v_z}{\partial y} - \frac{\partial v_y}{\partial z} \right) \mathbf{e}_x + \left(\frac{\partial v_x}{\partial z} - \frac{\partial v_z}{\partial x} \right) \mathbf{e}_y + \left(\frac{\partial v_y}{\partial x} - \frac{\partial v_x}{\partial y} \right) \mathbf{e}_z$, $\nabla \cdot (\mathbf{v} \otimes \mathbf{u}) = \frac{\partial}{\partial x} (v_x u_x + v_y u_x + v_z u_x) + \frac{\partial}{\partial y} (v_x u_y + v_y u_y + v_z u_y) + \frac{\partial}{\partial z} (v_x u_z + v_y u_z + v_z u_z)$

[illegible]

Note 4:

C ∇ a), a - () m_a (-), a m m , a a m (C a a
D a), m m (∇ a), a m m a m m (a a), a m ,
a m , a - , a m m a a m m (a a), a m , a , a
m (a D), m m (B), a m a (a a) a a m

[illegible]

Note 6:

(B_n), m n n n (B_n v), v m n n (v), m m v v v (v A),
n n m (D), nm n n D n n A) n n m n.

Note 7: ∇a m a a a m m a a (Ba) a C a m a m (∇ a).

Note 8: $\nabla^2 A = \nabla^2 m = \nabla^2 \bar{m} = 0$, $\nabla^2 m = \nabla^2 \bar{m} = 0$, $\nabla^2 m = \nabla^2 \bar{m} = 0$

D

2020, &D
 CA -
 &D C
 2020,
 &D
 C
 10
 11
 5
 1001
 DA
 D
 8
 20
 C876, - CD19 CA -
 B-
 D
 12
 3
 D
 (D);
 3
 (C A). A
 23
 (40m, 80m)
 (Ba)
 A
 11
 A
 D-19
 A
 B
 162 1
 2020.
 (: 汉曲优)
 C

Name of R&D project on drugs (products)		R&D stages as at the end of the Reporting Period in the PRC		R&D stages as at the end of the Reporting Period in other countries	
No.		R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	5 A -189 (C)	C			
2	C-411	C			
3	-1501	C		C	
4	C-437	C		C	
5		C			
6	-159	C			
7	-1001 (Note 1)	C		C	
8	D	C			
9	C-647 C	A			
10	C-207	A			
11	C-011 C	A			
12	C-338 (Note 2)	A		A	

Note 1: 5 A -189 (C) is a Phase I clinical trial in the PRC.

Note 2: A -1501 is a Phase I clinical trial in the PRC.

Name of R&D project on drugs (products)		R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
No.	Type	R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	B		A		
2	B		(Note 1)		
3	B				
4	B				
5	B				

Management

D A

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
6	B	<p>■ 2 D</p> <p>■ A</p>	A			
7	B	<p>■ 2 D</p> <p>■ A</p>	C			
8	B	<p>■ A -C A-4</p> <p>■ A</p>	A			
9	B	<p>■ A - A</p> <p>■ A</p>	A			
10	B	<p>■ A /</p> <p>■ A -CD20</p>	C			(Note 4)
11	B	<p>■ A -</p> <p>■ A</p>	A			
12	B	<p>■ A - 2</p> <p>■ A</p>	C		A	
13	B	<p>■ A -</p> <p>■ A</p>	C		A	
14	B	<p>■ A - D-1</p> <p>■ A</p>	C		A	
15	B	<p>■ A - D- 1</p> <p>■ A</p>	A		C	
16	B	<p>■ 22</p> <p>■ A</p>	C			(Note 8)
17	B	<p>■ 55</p> <p>■ A</p>	C			
18	B	<p>■ 56</p> <p>■ A</p>	A			
19	C	<p>■ A - D-1</p> <p>■ A</p>	C			(Note 10)

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
20	C M A A M	C M A - D-1 A A M A A - M A A	A			
21	C M A A M	C M A - D-1 A A (C A + 5) A A A A C A	C	A A		
22	C M A A M	C M A - D-1 A A (C A -) A A C A	C	A A		C A A
23	C M A A M	C M A - D-1 A A C M A - / A A A C	C	A A		
24	C M A A M	C M A - D-1 A A (C A - A M -) A A - A M A A A A - M C	C	A A		C A A
25	C M A A M	C M A - D-1 A A A M - A A A A A C C A A - C M A	C	A A		

Note 1: A 2020, 2,000 2,000
500 150 150
A. 2020,

[illegible]

D A

A 3, 11/12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846,

16 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Interim Report 2020 17

Management

D A

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The management has also identified several opportunities for improvement, including the need to enhance the Company's financial controls and internal controls. The management has taken several steps to address these issues, including the implementation of new financial controls and internal controls, and the appointment of a new Chief Financial Officer. The management believes that these steps will help to improve the Company's financial performance and operations in the future.

Medical Devices and Medical Diagnosis

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The management has also identified several opportunities for improvement, including the need to enhance the Company's financial controls and internal controls. The management has taken several steps to address these issues, including the implementation of new financial controls and internal controls, and the appointment of a new Chief Financial Officer. The management believes that these steps will help to improve the Company's financial performance and operations in the future.

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The management has also identified several opportunities for improvement, including the need to enhance the Company's financial controls and internal controls. The management has taken several steps to address these issues, including the implementation of new financial controls and internal controls, and the appointment of a new Chief Financial Officer. The management believes that these steps will help to improve the Company's financial performance and operations in the future.

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The management has also identified several opportunities for improvement, including the need to enhance the Company's financial controls and internal controls. The management has taken several steps to address these issues, including the implementation of new financial controls and internal controls, and the appointment of a new Chief Financial Officer. The management believes that these steps will help to improve the Company's financial performance and operations in the future.

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The management has also identified several opportunities for improvement, including the need to enhance the Company's financial controls and internal controls. The management has taken several steps to address these issues, including the implementation of new financial controls and internal controls, and the appointment of a new Chief Financial Officer. The management believes that these steps will help to improve the Company's financial performance and operations in the future.

D-19 2019. 6.85% 2019;
 B1,359 81.43% 2019, 2019;
 B2 98.40% 2019.
 3 4 .
 37.8%

[illegible]

D

A - m n , n . B n n , n n 11 m n
n n , w m n n n m n n n
n n , A nm m , 2 n n n n n n
n . D , nm m n n n n Cn ■ n nm n n
n n . n n n n , w n n n n n ,
w 5 Cn n n 3 Cn n m n m , n n n
m n n n n n S C n n w n n n
n n , n w m n n n n n n
w n m m n . C n ■ n n S n w ■ n n n n
n w n n n w m n n n n

[illegible]

Management

D A

2020, 30, 7,047, B11,016, 24.59%, 2020, 23.59%.

C D-19, B35,873, 23.59%.

Internal Integration and Operation Enhancement

D, 4, B, D, A, 2020, 23.59%.

2020, 30, 7,047, B11,016, 24.59%, 2020, 23.59%.

C D-19, B35,873, 23.59%.

(1) *Analysis of Changes in Relevant Items of Income Statement and Statement of Cash Flows*

$$: \text{M} \quad \text{C} \quad : \quad \text{B}$$

Note 1: D

Note 2: &D

Note 3:

Note 4:

Note 5:

(2) R&D expenditure
&D

	: m	C	:	B
&D				1,204
&D	n n			485
<hr/>				
n &D				1,689
<hr/>				
n &D	n n	n (%)		12.0
&D	n m n	n m n n	n &D m n n	n
	m	n m n n	n &D m (%)	15.4
n	&D	n n (%)		28.69

D

[illegible]

B. Analysis of Segment and Regional Operations

(1) Principal Operations by Segments and Products

: m C : ▼ B

Principal operations by segments							
By segments	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin	
上海医药 (Note 1)	9,952	3,754	62.28	7.97	3.79	▼	4.27
上海医药 上海医药	2,639	1,309	50.40	47.18	49.21	▼	0.68
上海医药 (Note 2)	1,359	1,130	16.82	6.85	4.68	▼	9.16

Principal operations by products							
Products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin	
上海医药 (Note 3)	1,767	278	84.26	2.19	4.51	▼	0.38
上海医药 (Note 4)	422	119	71.89	59.94	71.10	▼	1.83
上海医药 (Note 5)	1,800	631	64.93	22.77	1.68	▼	7.52
上海医药 (Note 6)	755	48	93.63	38.35	16.94	▼	1.64
上海医药 (Note 7)	1,248	484	61.20	9.49	20.22	▼	3.46
上海医药 (Note 8)	247	20	91.74	41.03	0.42	▼	3.37
上海医药 A	452	330	27.11	32.97	31.29	▼	1.79

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
C	9,894	4,093	58.63	8.30	11.40	7.32
	4,071	2,123	47.84	23.53	10.29	6.26
Note 1:	<p> 2019年1-6月，公司实现营业收入9,894万元，较上年同期增长8.30%；营业成本4,093万元，较上年同期增长11.40%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					
Note 2:	<p> 2019年1-6月，公司实现营业收入4,071万元，较上年同期增长23.53%；营业成本2,123万元，较上年同期增长10.29%。毛利率为47.84%，较上年同期提高6.26个百分点。 </p>					
Note 3:	<p> 2019年1-6月，公司实现营业收入2.19%，较上年同期增长2.19%；营业成本2.19%，较上年同期增长2.19%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					
Note 4:	<p> 2019年1-6月，公司实现营业收入59.94%，较上年同期提高59.94%；营业成本59.94%，较上年同期提高59.94%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					
Note 5:	<p> 2019年1-6月，公司实现营业收入22.77%，较上年同期提高22.77%；营业成本22.77%，较上年同期提高22.77%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					
Note 6:	<p> 2019年1-6月，公司实现营业收入38.35%，较上年同期提高38.35%；营业成本38.35%，较上年同期提高38.35%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					
Note 7:	<p> 2019年1-6月，公司实现营业收入9.49%，较上年同期提高9.49%；营业成本9.49%，较上年同期提高9.49%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					
Note 8:	<p> 2019年1-6月，公司实现营业收入41.03%，较上年同期提高41.03%；营业成本41.03%，较上年同期提高41.03%。毛利率为58.63%，较上年同期提高7.32个百分点。 </p>					

D A

(1) Operation and Results of Major Subsidiaries of the Group

$$\vdash B$$
[illegible]

Note: ♪ ♪ ♪ ♪ ♪ ♪ ♪ ♪ ♪♯ ♪ ♪ ♪ ♪ ♪ .

B 5 m

$$:\nabla^B$$

Name of subsidiary	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Net profit
S. A. S. (Note 1)	R&D		543	5,536	3,708	110	448
C. A. S. (Note 2)	R&D		50	2,528	1,728	686	41
S. A. S. (Note 1)	R&D		N/A	2,745	2,302	504	40

Note 1:

	a	b	c	d	e	f	g	h	i	j	k	l	m	n	o	p	q	r	s	t	u	v	w	x	y	z
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z

2020

[illegible]

(2) Operation and Results of Investee Companies whose Net Profit and Investment Income Contributing More Than 10% of the Group's Net Profit

										: M		: B							
Name of investee		Nature of business		Principal activities		Registered capital		Total assets		Net assets		Revenue		Operating profit					
S		A M		A		A M A		A		100		307,273		84,008		203,765		4,808	

D A

29 2020,

१ C १ ■ १ , १ M १ , W १ M .

$\frac{1}{\sqrt{2}}$ $\frac{1}{\sqrt{2}}$ $\frac{1}{\sqrt{2}}$ $\frac{1}{\sqrt{2}}$ $\frac{1}{\sqrt{2}}$

$$: \text{M} \quad \text{C} \quad : \quad \text{B}$$

D. Core Competitiveness Analysis

[illegible][illegible][illegible][illegible]

ଲକ୍ଷ୍ୟ ୨୦୨୦, ଲକ୍ଷ୍ୟ C D-19 ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ
 ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ
 ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ ଲକ୍ଷ୍ୟ

[illegible]

[illegible][illegible]

- W' a a a a M' W' -
 - a a , a a &D a a a a a M' a M' .
 W' a a a a a W' a a M'a a M' a W' a a
 a a a M' M' M' C a a , M'a^K a a M' , a
 W' M' M' M' a M' a M'a a M'a a .

[illegible][illegible]

$\nabla \cdot \vec{w} = w_x + w_y$

Management

D A

2020, the Company's operating income increased by 10.5% compared with the same period of the previous year, and the net profit attributable to shareholders increased by 12.3%.

Healthcare Services

2020, the Company's healthcare services business continued to expand. The Company's healthcare services business includes the operation of hospitals, medical clinics, and medical research institutions. The Company's healthcare services business has a strong competitive advantage in the field of medical research and development, and the Company's healthcare services business has a strong competitive advantage in the field of medical research and development.

(D) (B S).

C m S. (重慶星榮整形醫院), C ' (上海星晨兒童醫院) a

Pharmaceutical Distribution and Retail

2020, the Company's pharmaceutical distribution and retail business continued to expand. The Company's pharmaceutical distribution and retail business includes the operation of pharmaceutical distribution and retail companies, and the Company's pharmaceutical distribution and retail business has a strong competitive advantage in the field of pharmaceutical distribution and retail.

Financing

2020, the Company's financing business continued to expand. The Company's financing business includes the operation of financing companies, and the Company's financing business has a strong competitive advantage in the field of financing.

3. Potential Risks

I. Risks in relation to industry policies and system reforms

The Company's business is highly dependent on the government's policies and system reforms. The Company's business is highly dependent on the government's policies and system reforms. The Company's business is highly dependent on the government's policies and system reforms. The Company's business is highly dependent on the government's policies and system reforms. The Company's business is highly dependent on the government's policies and system reforms.

&D a

C a

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

II. Market risks

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

III. Business and operating risks

(1) R&D risk of drugs

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

אשר נכנסו לתחולת חוק המס הכנסה, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף, וכן אלו אשר נכנסו לתחולת חוק המס הערך המוסף.

(2) Control risk of product/service quality

The Company has established a quality management system to ensure the quality of its products and services. The system covers the entire process from raw material procurement to final product delivery. The Company has implemented a series of measures to control the quality risk, including:

- 1. Establishing a quality management system and implementing it effectively.
- 2. Strengthening the quality control of raw materials and components.
- 3. Improving the production process and ensuring the stability of the product quality.
- 4. Strengthening the quality control of the finished products and ensuring the delivery of high-quality products to the customers.
- 5. Establishing a quality feedback mechanism and continuously improving the product quality.

Through the implementation of these measures, the Company has effectively controlled the quality risk and ensured the high quality of its products and services.

(3) Safety and environmental risks

The Company has established a safety and environmental management system to ensure the safety of its operations and the protection of the environment. The system covers the entire process from raw material procurement to final product delivery. The Company has implemented a series of measures to control the safety and environmental risk, including:

- 1. Establishing a safety and environmental management system and implementing it effectively.
- 2. Strengthening the safety and environmental control of raw materials and components.
- 3. Improving the production process and ensuring the safety and environmental protection of the product quality.
- 4. Strengthening the safety and environmental control of the finished products and ensuring the delivery of safe and environmentally friendly products to the customers.
- 5. Establishing a safety and environmental feedback mechanism and continuously improving the product safety and environmental protection.

Through the implementation of these measures, the Company has effectively controlled the safety and environmental risk and ensured the safety of its operations and the protection of the environment.

IV. Management risks

(1) *Internationalized risks*

[illegible]

(2) *Risks arising from acquisitions and reorganizations*

$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) e^{-x^2} dx = \frac{1}{\sqrt{\pi}}$

V. Foreign exchange risk

[illegible]

VI. Force majeure risks

[illegible]

4. Other Events

A. 2019 Shareholding Increase Plan of the Controlling Shareholder

A □ (/) C , 19% 2019,

A / □ C) 12 19% 2019

(), B100 . 2019 2,562,898,545) () 2% 12- 2019 A , 2019 16,369,500 C 19

▼B369.81 , 0.64% C 19

RESULTS AND DIVIDENDS

As at the end of the reporting period, the Company's total assets were RMB 41,777 million, an increase of 1.3% compared with the end of the reporting period of the previous year. The total liabilities were RMB 17,000 million, an increase of 1.3% compared with the end of the reporting period of the previous year. The total equity was RMB 24,777 million, an increase of 1.3% compared with the end of the reporting period of the previous year.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Sell back of "17 Fosun 01" Corporate Bond

On May 5, 2020, the Company's Board of Directors resolved to sell back the "17 Fosun 01" Corporate Bond (1,580,500,000 RMB) at the par value of RMB 100 per bond. The Company has completed the sell back of the "17 Fosun 01" Corporate Bond on May 17, 2020. The total amount of the sell back was RMB 10,919,500,000. The Company has also completed the redemption of the "17 Fosun 01" Corporate Bond on May 17, 2020. The total amount of the redemption was RMB 10,919,500,000. The Company has also completed the redemption of the "17 Fosun 01" Corporate Bond on May 17, 2020. The total amount of the redemption was RMB 10,919,500,000.

DIRECTORS

The Company's Board of Directors consists of 11 members, including 4 independent non-executive directors and 7 executive directors.

Executive Directors

- Mr. Chen Qizhi (陳啟宇) (Chairman)
- Ms. Yao Fang (姚方) (Co-Chairman)
- Ms. Wu Yifang (吳以芳) (President and Chief Executive Officer)

Non-executive Directors

- Mr. Xu Xiaoliang (徐曉亮)
- Mr. Gao Ping (龔平)
- Mr. Pan Donghui (潘東輝)

Independent Non-executive Directors

- Mr. Jiang Hui (江惠)
- Mr. Huang Tianyu (黃天祐)
- Ms. Li Ling (李玲)
- Mr. Tang Yuliang (湯谷良)

On May 17, 2020, the Company's Board of Directors resolved to sell back the "17 Fosun 01" Corporate Bond (1,580,500,000 RMB) at the par value of RMB 100 per bond. The Company has completed the sell back of the "17 Fosun 01" Corporate Bond on May 17, 2020. The total amount of the sell back was RMB 10,919,500,000. The Company has also completed the redemption of the "17 Fosun 01" Corporate Bond on May 17, 2020. The total amount of the redemption was RMB 10,919,500,000. The Company has also completed the redemption of the "17 Fosun 01" Corporate Bond on May 17, 2020. The total amount of the redemption was RMB 10,919,500,000.

Statutory D

SUPERVISORS

A ३ , १ C mm १ . १ २ २

▲ (任倩) (Chairman)

曹根興

▼ ㊦ ㊧ (管一民)

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

▼ . C , a D , a a a - Ba (i^k : 01761), a m a

股份有限公司) (01818), 24 A 2020. * (招金礦業)

(公司) (K : 00755), 23 A 2020.

申通地鐵股份有限公司 (600834), 9 2020. (上海)

D. * (長飛光纖光纜股份有限公司) (: 601869, 06869), 於 2020 年 17 月 2020 年 13 月 2020.

B. * (青島銀行股份有限公司) (: 002948, 03866), 於 2020 年 13 月 2020.

(上海華誼集團股份有限公司) (600623) 2020.

D. 13.51(2)

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. 25 2019.
 ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. () ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. ()
 ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. () ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. ()
 ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. () ଶ୍ରୀ ରାମଚନ୍ଦ୍ର ମହାପାତ୍ର, ଏମ୍.ଏଲ୍.ଏ. ()

[illegible]

27 2019, 154,950 103 102 154,650 1%

17 2020, (1) (10) A

D

Participant	Date of Grant (dd-mm-yyyy)	Vesting Date (dd-mm-yyyy) ⁽¹⁾	Option share ⁽¹⁾	Exercise Period ⁽¹⁾	Outstanding options as at 1 January 2020	Adjusted during the Reporting Period ⁽²⁾	Exercise price per share ⁽³⁾	Forfeited or lapsed during the reporting period ⁽⁴⁾	Outstanding options as at 30 June 2020
		26-6-2020		26-6-2020 26-6-2029					
		31-3-2021	40%	31-3-2021 26-6-2029					
		31-3-2022		31-3-2022 26-6-2029					
	27-6-2019	31-3-2021	30%	31-3-2021 26-6-2029	151,350	1,362,150	542	(20,000)	1,493,500
		31-3-2022		31-3-2022 26-6-2029					
		31-3-2022	30%	31-3-2022 26-6-2029					

Note:

- (1) 17 2020.
- (2) 17 2020.
- (3) D , 3 20,000
- (4) D

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2020, the interests and short positions of the substantial shareholders in the shares and underlying shares of the Company, as required by Rule 2.26 of the Listing Rules, are as follows:

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
■	B	■	48,803,000 () ⁽²⁾	8.84%
■	B	AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
▼		■	48,803,000 () ⁽²⁾	8.84%
		AS	938,095,290 () ⁽²⁾	46.65%
	B	AS	114,075 ()	0.01%
		■	38,723,000 ()	7.02%
B		■	38,707,016 ()	7.01%
B		■	28,195,990 ()	5.11%
			782,000 ()	0.14%

Notes:

(1) () : ()

(2) The percentage of shares held by the substantial shareholders is calculated based on the total number of shares of the Company in issue as at 30 June 2020, which is 552,898,290 shares. The percentage of shares held by the substantial shareholders is 71.09% for the shares of the Company and 85.29% for the underlying shares of the Company.

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

During the period from 1 January 2020 to 30 June 2020, none of the directors or supervisors of the Company has exercised any rights to acquire shares or debentures of the Company or any other entity.

C m a a a C a a m a C a a a .

COMPLIANCE WITH THE CG CODE

A b m a w s a a s f a a ■ s f a , C m a a m a

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

21. 09. 2020, 17.00. Ca. 10 - D. 10 min. 10 min. A.

30 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 2680, 2681, 2682, 2683, 2684, 2685, 2686, 2687, 2688, 2689, 2690, 2691, 2692, 2693, 2694, 2695, 2696, 2697, 2698, 2699, 2700, 2701,

[illegible][illegible]

১. মম
 ২. মম
 ৩. মম
 ৪. মম
 ৫. মম
 ৬. মম
 ৭. মম
 ৮. মম
 ৯. মম
 ১০. মম

_____ B 4 _____ B 4

25 A 2020

Interim Condensed Consolidated



For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
REVENUE	5	13,965,179	14,085,146
C		(6,215,872)	(5,598,983)
		7,749,307	8,486,163
	6	180,429	109,724
		(3,931,067)	(4,998,448)
		(1,322,239)	(1,147,889)
		(1,204,425)	(849,383)
		(42,765)	(21,918)
	7	603,622	389,686
		(52,138)	(45,617)
		96,436	86,650
	8	(427,878)	(546,940)
		(46,558)	(25,933)
		698,964	760,055
PROFIT BEFORE TAX	9	2,301,688	2,196,150
	10	(392,081)	(376,521)
PROFIT FOR THE PERIOD		1,909,607	1,819,629
		1,714,710	1,516,120
		194,897	303,509
		1,909,607	1,819,629
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
Ba		RMB0.67 Yuan	▼ B0.59
D		RMB0.67 Yuan	▼ B0.59


Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 30 2020

For the six months ended 30 June

	2020 RMB'000 (Unaudited)	2019 RMB'000 ()
PROFIT FOR THE PERIOD	1,909,607	1,819,629
OTHER COMPREHENSIVE (LOSS)/INCOME		
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	(227,651)	70,799
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	72,684	(26,824)
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	(154,967)	43,975
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	1,754,640	1,863,604
Attributable to:		
Parent Company	1,660,547	1,544,923
Non-controlling interests	94,093	318,681
	1,754,640	1,863,604

Interim Condensed Consolidated



30 June 2020

	Notes	30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	13	11,313,846	10,720,960
Intangible assets		2,389,837	2,454,742
Investments in subsidiaries		9,093,050	9,013,990
Investments in associates		9,238,300	9,036,246
Financial assets at fair value through profit or loss		356,204	381,332
Financial assets at fair value through other comprehensive income		21,712,444	20,491,557
Prepaid expenses and deposits		60,945	107,709
Other non-current assets		1,851,891	1,983,155
Deferred tax assets		236,457	196,095
		1,300,703	1,273,605
		57,553,677	55,659,391
CURRENT ASSETS			
Financial assets at fair value through profit or loss	14	4,561,539	3,940,537
Financial assets at fair value through other comprehensive income		5,271,488	4,607,722
Accounts receivable		1,628,029	1,420,087
Prepaid expenses and deposits		992,812	456,651
Other current assets		354,915	445,103
Deferred tax assets		9,750,416	9,533,268
		22,559,199	20,403,368
CURRENT LIABILITIES			
Accounts payable	15	2,864,017	2,397,315
Other payables and provisions		6,116,649	5,376,193
Contract liabilities	16	12,404,601	8,560,202
Financial liabilities at fair value through profit or loss		138,571	143,786
Financial liabilities at fair value through other comprehensive income		527,652	503,683
Other current liabilities		487,052	452,587
		22,538,542	17,433,766
NET CURRENT ASSETS		20,657	2,969,602
TOTAL ASSETS LESS CURRENT LIABILITIES		57,574,334	58,628,993

		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
	Notes		
NON-CURRENT LIABILITIES			
Long-term debt	16	10,953,518	12,576,907
Long-term payable		369,340	410,188
Deferred income		2,928,227	2,994,048
Long-term equity investment		417,091	417,345
Long-term contract liability		2,891,682	2,860,170
Other non-current liabilities		215,655	223,009
		17,775,513	19,481,667
Net assets		39,798,821	39,147,326
EQUITY			
Equity attributable to owners of the parent			
Capital		2,562,899	2,562,899
Reserves		30,419,792	29,268,280
		32,982,691	31,831,179
Non-controlling interests		6,816,130	7,316,147
Total equity		39,798,821	39,147,326

Chen Qiyu
Director

Wu Yifang
Director

S a m C a

For the six months ended 30 June 2020

[illegible]

*		▼	B30,419,792,000 (31 D	▼	2019: B29,268,280,000)	
---	--	---	-----------------------	---	------------------------	--

2020

* 2017: 2018:		▼ B26,108,576,000 (31 D)	▼ B25,359,500,000
---------------	--	--------------------------	-------------------

Interim Condensed Consolidated



For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
	Notes		
Cash and cash equivalents		1,928,625	1,849,335
Less: cash equivalents		(467,328)	(399,147)
Net cash and cash equivalents		1,461,297	1,450,188
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditures		(1,904,148)	(2,040,985)
Acquisition of subsidiaries	17	(8,400)	(133,162)
Disposal of subsidiaries		(192,431)	(174,524)
Disposal of property, plant and equipment		(435,607)	(109,283)
Disposal of intangible assets		151,917	35,418
Disposal of financial assets		474,449	642,245
Disposal of other assets		—	2,296
Disposal of investments		67,961	41,866
Disposal of other investments		—	1,039
Disposal of other financial assets		18,718	20,053
Disposal of other non-current assets		1,708	—
Disposal of other non-current financial assets		5,439	26,015
Disposal of other non-current financial investments		50,228	—
Disposal of other non-current financial investments		(570,138)	570,562
Disposal of other non-current financial investments		(38,629)	39,801
Net cash and cash equivalents		(2,378,933)	(1,078,659)

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
30 2020

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

1. CORPORATE AND GROUP INFORMATION

The Group is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial year ends on 31 December. The Group's registered office is at the registered office of the Group's parent company, which is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial year ends on 31 December. The Group's registered office is at the registered office of the Group's parent company, which is a company incorporated in the Cayman Islands.

The Group is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial year ends on 31 December. The Group's registered office is at the registered office of the Group's parent company, which is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial year ends on 31 December. The Group's registered office is at the registered office of the Group's parent company, which is a company incorporated in the Cayman Islands.

The Group is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial year ends on 31 December. The Group's registered office is at the registered office of the Group's parent company, which is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial year ends on 31 December. The Group's registered office is at the registered office of the Group's parent company, which is a company incorporated in the Cayman Islands.

2. BASIS OF PREPARATION

The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group. The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group. The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group. The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group. The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group.

Amended to the Group's financial statements in accordance with the accounting policies and practices adopted by the Group. The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group. The Group has prepared these interim condensed consolidated financial statements in accordance with the accounting policies and practices adopted by the Group.

Definition of a Business
Interest Rate Benchmark Reform
Covid-19-Related Rent Concessions (early adopted)
Definition of Material

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

[illegible]

() Am m ■ 9, ■ A 39 a ■ 7 a a K a m a a .

am m m a w a a

a m a a m a , am m m a a a

ma a a a w a a a a m m

a a m a a a a w a a a a

a .

() Am m ■ § 16 ବ ବ ବ ବ ବ ମ ବ ବ
 ବ ବ -19 ବ ମ . ବ ବ
 ବ ବ -19 ବ ମ ବ () ବ ବ ବ ମ
 ବ ବ ବ ବ ବମ ବ , ବ , ବ ବ ମମ ବ
 ବ ; () ବ ବ ବ ମ ବ ବ ମ ବ 30 2021; ବ ()
 ବ ବ ମ ବ ବ . ବମ ମ ବ ବ
 ବ 1 2020 ବ ବ ବ ମ .

D		30	2020,	අ ම	අ අ ම	අ	'	අ
	අ අ	අ අ	-19	අ ම	අ	අ	ම	අ .
අ අ අ	අ ම ම	1	අ 2020	අ	අ	අ ම	අ	අ
අ	අ අ	-19	අ ම		30	2020.	A	, අ
අ අ ම	අ			B4,787,000.00	අ	අ	අ අ අ අ	අ අ ම
අ	අ අ	අ			30	2020.		

() Am m ■ A 1 a ■ A 8









































































































































































m m a a w m a . w a a m a a

a a a m m^K a a a a m . am m a a m a w

a m m m . am m a a m a m

a a m .

4. OPERATING SEGMENT INFORMATION

	<p>           </p>
	<p>           </p>
(a)	<p>           </p>
()	<p>           </p>
()	<p>           </p>
()	<p>           </p>
()	<p>           </p>
▼	<p>           </p>
	<p>           </p>
	<p>           </p>
	<p>           </p>
	<p>           </p>
	<p>           </p>
Σ	<p>           </p>
	<p>           </p>
Σ	<p>           </p>
	<p>           </p>

Notes to Interim Condensed Consolidated

2020

30 2020

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	Pharmaceutical manufacturing and R&D RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Adjustments and Eliminations RMB'000	Total RMB'000
Segment revenue:							
Revenue	9,952,096	2,638,887	1,359,017	—	15,179	—	13,965,179
Cost of sales	48,294	46,610	4,700	—	8,270	(107,874)	—
Revenue	10,000,390	2,685,497	1,363,717	—	23,449	(107,874)	13,965,179
Segment results*							
Profit	1,115,513	509,746	31,373	—	(4,289)	(19,026)	1,633,317
Operating expenses	135,673	10,551	16,910	—	16,579	—	179,713
Other income	157,704	14,210	3,393	—	275,233	30	450,570
Other expenses	56,129	10,345	17,531	—	185	(5,291)	78,899
Other income	(51,353)	(14,125)	(17,409)	—	(5,587)	26,170	(62,304)
Other expenses	27,605	(55,433)	(6,267)	—	(22,062)	—	(56,157)
Profit	(45,744)	—	—	—	(814)	—	(46,558)
Operating expenses	32,681	24,021	(31,134)	724,041	(50,645)	—	698,964
Other income	—	—	—	—	—	—	—
Other expenses	—	—	—	—	—	—	—
Other income	—	—	—	—	—	—	—
Other expenses	—	—	—	—	—	—	—
Profit	1,428,208	499,315	14,397	724,041	208,600	1,883	2,301,688
Operating expenses	(313,433)	(65,625)	(12,784)	—	(239)	—	(392,081)
Other income	—	—	—	—	—	—	—
Other expenses	—	—	—	—	—	—	—
Other income	—	—	—	—	—	—	—
Other expenses	—	—	—	—	—	—	—
Profit	1,114,775	433,690	1,613	724,041	208,361	1,883	1,909,607
Segment assets:							
Assets	41,047,332	8,262,367	9,812,781	13,877,770	4,251,314	(1,683,155)	75,568,409
Liabilities	349,474	—	—	—	6,730	—	356,204
Assets	2,248,581	1,102,609	1,624,283	13,877,770	2,859,201	—	21,712,444
Liabilities	—	—	—	—	—	—	4,544,467
Assets	—	—	—	—	—	—	80,112,876
Segment liabilities:							
Liabilities	18,654,179	1,937,780	2,229,824	—	386,141	(9,370,028)	13,837,896
Assets	—	—	—	—	—	—	26,476,159
Liabilities	—	—	—	—	—	—	40,314,055
Other segment information:							
Depreciation and amortization	590,999	96,170	133,901	—	15,197	—	836,267
Impairment losses	(32,251)	49,686	2,365	—	22,048	—	41,848
Other income	1,309,447	97,984	356,886	—	47,953	—	1,812,270

* The segment results are calculated based on the accounting policies and methods used by the segment management. The segment results are not audited.

** The segment results are calculated based on the accounting policies and methods used by the segment management. The segment results are not audited.

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2019 (unaudited)

	Revenue	Cost of sales	Gross profit	Operating expenses	Operating profit	Finance income	Finance costs
	B'000	B'000	B'000	B'000	B'000	B'000	B'000
Segment revenue:							
Revenue	10,814,123	1,792,865	1,458,512		19,646		14,085,146
Cost of sales	8,421	19,401	1,876		20,674	(50,372)	
	10,822,544	1,812,266	1,460,388		40,320	(50,372)	14,085,146
Segment results*							
Operating profit	1,204,721	291,795	168,982		10,328	(19,887)	1,655,939
Finance income	75,540	13,034	3,681		3,326		95,581
Finance costs	281,499	(3,481)	(748)	7,274	2,679		287,223
Other income	50,628	16,153	21,874		216	(1,236)	87,635
Other expenses	(56,712)	(9,467)	(12,032)		(6,320)	29,102	(55,429)
	(15,616)	(22,095)	(15,446)		1,121		(52,036)
Profit before tax	(25,565)	477	(13,655)	774,939	(845)		(25,933)
Income tax expense	37,529	(25,330)	(13,655)		(13,428)		760,055
Profit after tax							115,621
Other income							(491,511)
Other expenses							(180,995)
Profit after tax and other income/exp	1,552,024	261,086	152,656	782,213	(2,923)	7,979	2,196,150
Other income	(319,655)	(30,673)	(51,774)		(258)		(402,360)
Other expenses							25,839
	1,232,369	230,413	100,882	782,213	(3,181)	7,979	1,819,629
Segment assets:							
Assets	36,425,494	6,874,258	10,781,464	12,429,996	4,362,843	(1,490,584)	69,383,471
Liabilities	399,018	12,808			9,134		420,960
Other income/exp	2,153,707	948,143	3,232,275	12,429,996	3,085,411		21,849,532
							4,249,250
							73,632,721
Segment liabilities:							
Liabilities	15,346,659	1,505,277	1,698,142		281,002	(8,590,276)	10,240,804
Other income/exp							28,931,431
							39,172,235
Other segment information:							
Depreciation	502,504	85,220	133,338		19,190		740,252
Amortisation	2,435	19,425	6,493		(2,198)		26,155
Other income/exp	1,016,436	85,165	160,766		95,489		1,357,856

* Segment results are presented on a cost of sales basis. The results are presented on a cost of sales basis, which is the basis used for the purpose of the segment information.

** The results are presented on a cost of sales basis, which is the basis used for the purpose of the segment information. The results are presented on a cost of sales basis, which is the basis used for the purpose of the segment information.

Notes to Interim Condensed Consolidated

2020

30 2020

5. REVENUE

Revenue is derived from the sale of pharmaceutical products.

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
Revenue from contracts with customer		13,951,418	14,066,560
Revenue from other contracts		13,761	18,586
		13,965,179	14,085,146

Disaggregated revenue information for revenue from contracts with customer
For the six months ended 30 June 2020 (unaudited)

Notes to Interim Condensed Consolidated



30 June 2020

5. REVENUE (Continued)

For the six months ended 30 June 2019 (unaudited)

	Revenue	Cost of sales	Gross profit	Research and development	Other income
	B'000	B'000	B'000	B'000	B'000
Types of goods or services					
Revenue	10,564,090	1,671,542	27,181		12,262,813
Cost of sales	238,771	111,402	1,430,327	2,144	1,782,644
Revenue	11,182	9,921			21,103
Revenue	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Geographical markets					
Revenue	8,288,825	1,024,242	1,457,508	406	10,770,981
Cost of sales	2,525,218	768,623		1,738	3,295,579
Revenue	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Timing of revenue recognition					
Revenue	10,575,272	1,681,463	27,181		12,283,916
Cost of sales	128,209	41,595	1,430,327	2,144	1,602,275
Revenue	110,562	69,807			180,369
Revenue	10,814,043	1,792,865	1,457,508	2,144	14,066,560

Notes to Interim Condensed Consolidated

2020

30 2020

6. OTHER INCOME

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
D	20,391	17,523	
	158,367	92,104	
	1,671	97	
	180,429	109,724	

7. OTHER GAINS

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
	87,209	27,528	
	439,102	327,405	
	—	2,186	
	77,311	32,567	
	603,622	389,686	

8. FINANCE COSTS

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
	425,687	543,161	
	12,188	12,355	
	(9,997)	(8,576)	
	427,878	546,940	

1 2 3 4

9. PROFIT BEFORE TAX

For the six months ended 30 June

	2020 RMB'000 (Unaudited)	2019 B'000 ()
C	4,932,900	4,263,438
C	1,282,972	1,335,545
5. 2. (D) 'A C ' m a) 5. 2. 2. a m : D A m m a : D 5. 2. 2. a m	2,468,297 66,453 83,795 39,516	1,952,209 134,290 67,904 46,956
	2,658,061	2,201,359
a a m : C : m a &D * a a	1,167,594 46,028	816,188 12,128
	1,121,566	804,060
a m m a m a a D a , a a m D a - - a Am a a a (a)/ m a m a , a a m m a m a a a a a a a a a a a a , a a , a a m	12,963 490,945 91,076 254,247 (917) 42,765 (439,102) (69,551) (1,621)	10,981 458,599 74,916 206,737 4,237 21,918 (327,405) (6,028) (18,465)

*
 १०
 २०
 ३०
 ४०
 ५०
 ६०
 ७०
 ८०
 ९०
 १००

Notes to Interim Condensed Consolidated

附 表 公 司

30 2020

10. INCOME TAX

本公司适用的企业所得税税率如下：25% (2019: 25%)
 1 2008, 0%
 20%.

本公司适用的企业所得税税率如下：16.5%
 9.48%.
 34.94% 1 A 2018 31 2019 25.17% 31
 2019. B AB (B), C
 22%. AS ()
 33.33%.

30 2020 2019

	For the six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 B'000 ()
C	467,327	464,045
D	(75,246)	(87,524)
	392,081	376,521

11. DIVIDENDS

D 30 2020 ()
 30 2019:).
 B0.39 ()
 31 D 2019
 30 2020.

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

For the six months ended 30 June 2020, the Group's earnings per share attributable to ordinary equity holders of the parent were RMB1.714710 (2019: RMB1.516120).

The Group's earnings per share attributable to ordinary equity holders of the parent for the six months ended 30 June 2020 were calculated as follows:

For the six months ended 30 June

	For the six months ended 30 June 2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Earnings	1,714,710	1,516,120
Number of shares	2,562,898,545	2,563,006,778
Earnings per share	1.714710	1.516120

For the six months ended 30 June

	For the six months ended 30 June 2020 (Unaudited)	2019 (Unaudited)
Shares	2,562,898,545	2,563,006,778
Weighted average number of shares	2,562,898,545	2,563,006,778

For the six months ended 30 June 2020.

13. PROPERTY, PLANT AND EQUIPMENT

Cash	11,313,846
------	------------

▼ B217,305,000 (31 D 2019: ▼ B133,709,000), 16

30 June 2020 RMB'000 (Unaudited)

[illegible]

1 2 3 4

61

Notes to Interim Condensed Consolidated

2020

30 2020

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

	Notes	30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
Bank borrowings:	(1)	486,008	344,186
		15,096,396	13,762,714
		15,582,404	14,106,900
Other borrowings:	(2)	899,616	
	(3)	6,876,099	7,030,209
		23,358,119	21,137,109
		(12,404,601)	(8,560,202)
		10,953,518	12,576,907
Analysis of bank borrowings:			
		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
1. Short-term bank borrowings:		12,404,601	8,560,202
2. Long-term bank borrowings:		7,833,867	6,860,077
3. Other bank borrowings:		2,633,443	5,395,435
4. Other bank borrowings:		486,208	321,395
		23,358,119	21,137,109
		(12,404,601)	(8,560,202)
		10,953,518	12,576,907

1 2 3 4

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

(1) **Bank loans**

(2) **Super Short-term Commercial Paper**

(3) Corporate bonds

[illegible]

17. BUSINESS COMBINATION

[illegible]

$\mathbb{W} : \quad$

[illegible]

Notes to Interim Condensed Consolidated

2020 2019 2018 2017

30 June 2020

17. BUSINESS COMBINATION (Continued)

A 2020 2019 2018 2017		
		B'000 (A)
C 2020 2019 2018 2017		(10,970)
C 2020 2019 2018 2017		14,529
2020 2019 2018 2017 31 D 2019		3,559 (11,959)
		(8,400)

18. COMMITMENTS

2020 2019 2018 2017		
		B'000 (A)
30 June 2020 RMB'000 (Unaudited)		31 D 2019
C 2020 2019 2018 2017		2,316,640 2,191,767
2020 2019 2018 2017		880,140 929,930
2020 2019 2018 2017		253,149 273,236
A 2020 2019 2018 2017		4,434,832 4,285,335
		7,884,761 7,680,268

19. RELATED PARTY TRANSACTIONS

[illegible]

For the six months ended 30 June

2019

B'000

(۱)

66 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Notes to Interim Condensed Consolidated



30 June 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

	Six months ended 30 June	
	2020	2019
	RMB'000 (Unaudited)	B'000 ()
From C. (notes 4 & 6 & 15)	128,644	125,937
From A. (notes 3 & 4 & 11 & 16)	96,578	1,156
From C. (notes 4 & 9)	87,769	8,899
From C. (notes 1 & 4 & 16)	2,266	410
From A. (notes 1 & 4)	1,071	1,164
From A. (notes 1 & 4)	1,007	2,126
From A. (notes 2 & 4 & 17)	907	85
From D. (notes 4 & 9)	510	3,352
From (notes 4 & 9)	33	
From (notes 1 & 4)	23	
From B. (notes 1 & 4)	—	1,318
From C. (notes 1 & 4 & 18)	—	1,228
	318,808	145,675

(c) Leasing and property management services

	Six months ended 30 June	
	2020	2019
	RMB'000 (Unaudited)	B'000 ()
As lessor		
From B. (notes 2 & 5)	6,106	5,310
From (notes 3 & 5 & 12 & 16)	3,529	7,895
From (notes 1 & 5)	733	
From (notes 2 & 5 & 17)	578	325
From D. (notes 5 & 7)	471	454
From (notes 1 & 5 & 6)	413	131
From (notes 2 & 5)	216	
From (notes 1 & 5)	145	86
From C. (notes 1 & 5)	65	
From (notes 1 & 5)	—	264
	12,256	14,465

19. RELATED PARTY TRANSACTIONS (Continued)

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
As lessee	(Unaudited)	()
Prepaid expenses and deposits (notes 3 & 5 & 13 & 16)	2,952	5,477
Duties and taxes payable (notes 5 & 9)	117	114
Interest payable (notes 5 & 9)	43	41
Accounts payable B C., (notes 5 & 9)	—	2,500
	3,112	8,132

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	(Audited)
Property management services	6,904	6,651

C m v v v v v m w v C v m (v),
v v v v v C m v v v ,
, w m v v v v v v C v B i K v C mm v m
1 v v 2020 v 31 D m 2022. m m m v v v v v w
v ▼B1,000,000,000. m m m v v v v v v

▼B1,000,000,000.

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
Maximum daily outstanding balance of deposits in Fosun Finance	(Unaudited)	()
9 C 9 M (notes 8 & 16)	979,619	574,422

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

	30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
A loan from a related party		
Loan from C, (notes 8 & 16)	52,274	38,779

Loan from C, (notes 8 & 16) is a loan with a term of 12 months, interest rate of 3%, and is repayable on 31 Dec 2020. The loan is secured by the personal guarantee of the directors and shareholders of the Company. The loan is classified as a financial asset at amortized cost.

Loan from D, (notes 8 & 16) is a loan with a term of 12 months, interest rate of 10%, and is repayable on 31 Dec 2020. The loan is secured by the personal guarantee of the directors and shareholders of the Company. The loan is classified as a financial asset at amortized cost.

	30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
Loans to related parties		
Loan to A, (notes 1 & 16)	10,884	10,566
Loan to B, C, (notes 2 & 16)	188,840	188,840
	199,724	199,406

(e) Interest income from/to related parties

	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 RMB'000 (Audited)
Interest income		
Interest income from B, C, (notes 2 & 16)	4,706	2,002
Interest income from C, (notes 8 & 16)	3,358	1,845
Interest income from A, (notes 1 & 16)	160	154
	8,224	4,001

Notes to Interim Condensed Consolidated

2020

30 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)

During the period, the Group has entered into various financial transactions with related parties, including the provision of loans and the receipt of loans from related parties. The interest income from/to related parties is calculated based on the principal amount of the loans and the applicable interest rate. The interest income from/to related parties is recorded in the consolidated income statement as interest income from/to related parties.

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Interest expense		
Interest expense on bank loans	1,058	1,619

Notes:

- (1) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (2) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (3) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (4) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (5) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (6) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (7) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (8) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (9) The interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (10) D, the interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (11) D, the interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (12) D, the interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.
- (13) D, the interest expense on bank loans is calculated based on the principal amount of the loans and the applicable interest rate.

19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)

Notes (Continued)

- (14) During the period, the Group entered into various financial transactions with related parties, including the purchase of financial assets and the disposal of financial liabilities. The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- (15) The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- (16) The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- (17) The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- (18) The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.

(f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Audited)
Key management personnel of the Group	50,051	25,416
Key management personnel of subsidiaries	15,410	12,417
Key management personnel of associates	243	501
	65,704	38,334

(g) Outstanding balances with related parties

- () As at 30 June 2020, the Group's outstanding balances with related parties were RMB51,513,000 (31 December 2019: RMB4,030,000). The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- () As at 30 June 2020, the Group's outstanding balances with related parties were RMB983,814,000 (31 December 2019: RMB1,071,384,000). The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- () As at 30 June 2020, the Group's outstanding balances with related parties were RMB193,654,000 (31 December 2019: RMB212,705,000). The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- () As at 30 June 2020, the Group's outstanding balances with related parties were RMB3,942,000 (31 December 2019: RMB5,526,000). The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.
- () As at 30 June 2020, the Group's outstanding balances with related parties were RMB118,211,000 (31 December 2019: RMB46,027,000). The Group's policy is to enter into financial transactions with related parties on an arm's length basis and to ensure that the transactions are in the best interests of the Group.

Notes to Interim Condensed Consolidated

2020

19. RELATED PARTY TRANSACTIONS (Continued)

(g) Outstanding balances with related parties (Continued)

() A 30 2020, 881,705,000

1 2 3 4

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

१ २ ३ ४ ५ ६ ७ ८ ९ १० ११ १२ १३ १४ १५ १६ १७ १८ १९ २० २१ २२ २३ २४ २५ २६ २७ २८ २९ ३० ३१ ३२ ३३ ३४ ३५ ३६ ३७ ३८ ३९ ४० ४१ ४२ ४३ ४४ ४५ ४६ ४७ ४८ ४९ ५० ५१ ५२ ५३ ५४ ५५ ५६ ५७ ५८ ५९ ६० ६१ ६२ ६३ ६४ ६५ ६६ ६७ ६८ ६९ ७० ७१ ७२ ७३ ७४ ७५ ७६ ७७ ७८ ७९ ८० ८१ ८२ ८३ ८४ ८५ ८६ ८७ ८८ ८९ ९० ९१ ९२ ९३ ९४ ९५ ९६ ९७ ९८ ९९ १००

[illegible][illegible][illegible]

$\frac{m}{n} = \frac{m}{n}$

[illegible]

Notes to Interim Condensed Consolidated

2020

30 2020

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities (Continued)

2019:	B2,818,244,000	B DA
2018:	B2,643,984,000 (31 D	2019: B2,818,244,000) B DA

Fair value hierarchy

Assets measured at fair value:

As at 30 June 2020 (Unaudited)

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
2020	566	849	59,530	60,945
2019	1,097,737	52,959	1,694,007	2,844,703
2018	—	354,915	—	354,915
2017	1,098,303	408,723	1,753,537	3,260,563

As at 31 December 2019 (Audited)

	(1) B'000	(2) B'000	(3) B'000	B'000
2020	1,554	52,909	53,246	107,709
2019	561,348	52,734	1,825,724	2,439,806
2018	—	445,103	—	445,103
2017	562,902	550,746	1,878,970	2,992,618

Notes to Interim Condensed Consolidated



30 June 2020

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

人民币 千元 3 人民币 千元

For the six months ended 30 June 2020

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
A 1 2020	1,825,724	53,246
人民币 千元	118,774	—
人民币 千元	—	6,284
A	68,397	—
D	(321,675)	—
人民币 千元	2,787	—
A 30 2020	1,694,007	59,530

人民币 千元 3 人民币 千元

For the six months ended 30 June 2019

	B'000 ()	B'000 ()
A 1 2019	2,155,293	82,301
人民币 千元	231,452	—
人民币 千元	—	(29,271)
A	116,220	—
D	(332,911)	—
人民币 千元	3,116	(340)
人民币 千元	(386,601)	—
A 30 2019	1,786,569	52,690

Notes to Interim Condensed Consolidated

30 2020

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

As at 30 June 2020 (Unaudited)

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Am	—	—	2,643,984	2,643,984

As at 31 December 2019 (Audited)

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Am	—	—	209,286	209,286
Am	—	—	2,608,958	2,608,958
			2,818,244	2,818,244

	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 RMB'000
A 1 2 3	2,818,244	2,913,876
A	35,026	46,708
D 2	(209,286)	
A 30	2,643,984	2,960,584

D 1 2 3 2019: 1).

21. CONTINGENT LIABILITIES

As at 30 June 2020, the Group had no contingent liabilities as at 30 June 2019.

22. EVENTS AFTER THE REPORTING PERIOD

After the reporting period, the Group has not identified any events that require adjustment to the financial statements.

23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements were approved by the Board of Directors on 25 June 2020.

[illegible]

Definitions

§	C mm	§	C mm	C m a
§ a	W ■ a/	§ a	W ■ a C ., .*	(宿遷市鐘吾醫院有限責任公司) a C a ■ a* (宿遷市腫瘤醫院), a a C m a
§ a	a a ■ a	§ a	a a a a ▼ a a m a	C m a m * (宿遷市新星康復體檢有限公司), a a C m a
§ .	§ a	§ a	A m a, a	, a § a § a a
§ a	, § D § \$	D	C m a	
§ a		§ a		
§ .	DA	§ .	a D A m a	
W a	a m a	a	W a a B a m a	a C m a m * (江蘇萬邦生化醫藥集團有限責任公司), a a C m a
W	a ■ a	W	a ■ a m C m a	* (溫州老年病醫院有限公司), a a C m a
W		W	■ a a a	
W a	■ a	W a	■ a C ., .*	(武漢濟和醫院有限公司), a a C m a
W C		W C	§ a a D / a m	C m a * (《董事有關僱員進行證券交易的書面指引》)
a a m a		C	a a m a a C m a m	* (重慶藥友製藥有限責任公司), a a C m a
a C a	■ a	a C a	■ a m	* (珠海禪誠醫院有限公司), a a C m a
%				
, a		W C	a m	, a , a a ,
a C a	W a	a C a a	a a	, C a a .